MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tremors: Treatment"

  • 2022 International Congress

    Novel strategies based on sensory electrical stimulation to manage tremor in Parkinson’s disease. A pilot study.

    C. Montero Pardo, M. González Sánchez, A. Pascual Valdunciel, J. Sánchez Pérez, J. Camilo Moreno, F. Oliveira Barroso, F. Grandas, J. Luis Pons (Madrid, Spain)

    Objective: Tremor can be a disabling motor symptom in patients with Parkinson´s disease (PD) and in some patients is refractory to medication. Here we present…
  • 2022 International Congress

    Spinocerebellar ataxia 21 and phenotypic variability within a family

    M. Hull, M. Parnes, J. Jankovic (Houston, USA)

    Objective: We describe four patients within a family who presented to our movement disorders centers for evaluation of various symptoms including unsteady gait, tremor, and…
  • 2022 International Congress

    Analysis of tremor during grasp using ultrasound imaging.

    A. Iyer, X. Xue, D. Roque, N. Sharma (Raleigh, USA)

    Objective: To develop an ultrasound (US) image-based model for Essential and Parkinsonian tremor to be used in conjunction with functional electrical stimulation (FES) for tremor…
  • 2022 International Congress

    A phase 2b, randomized, dose-response study of SAGE-324/BIIB124 for the treatment of essential tremor: KINETIC 2 trial in progress

    R. Pahwa, A. Ellenbogen, R. Elble, K. Bankole, T. Dam, J. Fratantonio, J. Gaiha-Rohrbach, M. Qin, S. Garafola, M. Gerbasi, H. Colquhoun (Kansas City, USA)

    Objective: The phase 2b KINETIC 2 trial is a double-blind, randomized, placebo-controlled, dose-response study designed to evaluate SAGE-324/BIIB124 (SAGE-324) for the treatment of patients with…
  • 2022 International Congress

    Preclinical Characterization of Suvecaltamide for Essential Tremor

    E. Brigham, N. Shanks, S. Markova, L. Tan, J. Kramer, D. Huffman, M. Lee (Palo Alto, USA)

    Objective: To characterize the in vitro T-type calcium (CaV3) channel target pharmacology and in vivo anti-tremor profile of suvecaltamide (JZP385, CX-8998). Background: CaV3 channels, a…
  • 2022 International Congress

    Clinical effectiveness and economic impact of transcutaneous afferent patterned stimulation therapy for essential tremor in a real-world setting: protocol for a pragmatic trial

    D. Dai, J. Fernandes, LA. Ramel, H. Coetzer, V. Zraick, A. Samiian, L. Hennum (Woonsocket, USA)

    Objective: To determine the feasibility of delivery, clinical effectiveness, healthcare resource utilization (HCRU) and costs of transcutaneous afferent patterned stimulation (TAPS) therapy for the treatment…
  • 2022 International Congress

    Intraoperative quantification of MDS-UPDRS tremor measurements using 3D accelerometry

    A. Smid, J. Elting, J. van Dijk, E. Otten, D. Oterdoom, K. Tamasi, T. Heida, T. van Laar, G. Drost (Groningen, Netherlands)

    Objective: This study focuses on translating parkinsonian tremor tests to an objective method to rate tremor severity using 3D accelerometry, that can be used during…
  • 2022 International Congress

    Treatment of upper limb dystonic tremors: a retrospective study

    B. Gonzalez-Herrero, I. Di Vico, M. Edwards, F. Morgante (London, United Kingdom)

    Objective: Our study aimed to evaluate the clinical outcome of patients with upper-limb dystonic tremor (UL-DTs) treated at a tertiary hospital in London. Background: Tremor…
  • MDS Virtual Congress 2021

    Real-World Evidence Supports use of Transcutaneous Afferent Patterned Stimulation for Tremor Control in Veteran’s Affairs Essential Tremor Patients

    K. Colletta, S. Borucki, D. Fujikawa, C. Handforth, A. Phan, A. Killoran, A. Li, K. Rosenbluth (Hines, USA)

    Objective: This post-market analysis evaluated Transcutaneous Afferent Patterned Stimulation (TAPS) therapy for management of upper limb essential tremor in a cohort of Veteran Affairs (VA)…
  • MDS Virtual Congress 2021

    Randomised Controlled Trial Comparing Efficacy of Zonisamide 25 mg given in addition to standard treatment with standard treatment alone in Tremor dominant Parkinson’s Disease- A Pilot study.

    K. Pillai, V. Goyal, A. Srivastava, R. Rajan, P. Srivastava, M. Singh, V. V.Y, D. Radhakrishnan, A. Elavarasi, P. Bhat (New Delhi, India)

    Objective: To compare improvement in  tremor at 12 weeks with Zonisamide  given in  a dose of  25 mg  along with other ant- parkinsonian drugs as…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
  • 9
  • 10
  • …
  • 17
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Life expectancy with and without Parkinson’s disease in the general population
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • An atypical and interesting feature of Parkinson´s disease
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley